Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07285798 · ClinicalTrials.gov registry record · Phase 3
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Not yet
- Registry status
- Phase 3
- Development phase
- 176
- Enrollment target
NCT07285798 is a Phase 3 study that has not yet begun recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 176 participants.
The verdict
NCT07285798, a Phase 3 study, has not yet begun recruiting, sponsored by Bristol-Myers Squibb.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 176 participants
- Enrollment target
Study Summary
The purpose of this study is to assess KarXT + KarX-EC for the treatment of irritability associated with autism in children and adolescents.
Interventions
- DRUG KarXT
- DRUG KarX-EC
- DRUG KarXT + KarX-EC Matching Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2026-09-11 |
| Est. Completion | 2029-08-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07285798
The ClinicalTrials.gov registry entry for NCT07285798 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which KarXT is the first listed.
NCT07285798 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07285798 about?
NCT07285798 is a clinical study titled "A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder". The purpose of this study is to assess KarXT + KarX-EC for the treatment of irritability associated with autism in children and adolescents.
What is the current status of trial NCT07285798?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 176 participants. The study started on 2026-09-11. Estimated completion is 2029-08-04.
What interventions are being tested in trial NCT07285798?
The interventions under investigation include: KarXT (DRUG), KarX-EC (DRUG), KarXT + KarX-EC Matching Placebo (DRUG).
Who is sponsoring clinical trial NCT07285798?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.